Treatment of brain metastases from HER-2-positive breast cancer: Current status and new concepts

Future Oncology

Volumn 9, Issue 11, 2013, Pages 1653-1664

  Bartolotti, Marco ^a   Franceschi, Enrico ^a   Brandes, Alba A ^a  

^a Azienda USL di Bologna   (Italy)

Author keywords

brain metastases; breast cancer; lapatinib; trastuzumab

Indexed keywords

AFATINIB; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPOTHILONE B; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GRN 1005; INIPARIB; IRINOTECAN; LAPATINIB; METHOTREXATE; NAVELBINE; NERATINIB; SAGOPILONE; TAXANE DERIVATIVE; TEMOZOLOMIDE; TOPOTECAN; TPI 287; TRASTUZUMAB; UNCLASSIFIED DRUG; VELIPARIB;

ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; STEREOTACTIC RADIOSURGERY; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CHEMORADIOTHERAPY; FEMALE; HUMANS; QUINAZOLINES; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84887266985     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.90     Document Type: Review

References (77)

1. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS. Breast cancer metastasis to the central nervous system. Am. J. Pathol. 167(4), 913-920 (2005).
2. Brufsky AM, Mayer M, Rugo HS et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin. Cancer Res. 17(14), 4834-4843 (2011).
3. Sperduto PW, Kased N, Roberge D et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specifc tool to estimate survival for patients with brain metastases. J. Clin. Oncol. 30(4), 419-425 (2012).
4. Clayton AJ, Danson S, Jolly S et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br. J. Cancer 91(4), 639-643 (2004).
5. Kirsch DG, Ledezma CJ, Mathews CS et al. Survival after brain metastases from breast cancer in the trastuzumab era. J. Clin. Oncol. 23(9), 2114-2116; author reply 2116-2117 (2005).
6. Romond EH, Jeong JH, Rastogi P et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 30(31), 3792-3799 (2012).
7. Smith I, Procter M, Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555), 29-36 (2007).
8. Bria E, Cuppone F, Fornier M et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res. Treat. 109(2), 231-239 (2008).
9. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of HER-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7, 153 (2007).
10. +) breast cancer treated with adjuvant trastuzumab (T). J. Clin. Oncol. 30, Abstract 609 (2012).
11. Xu Z, Marko NF, Chao ST et al. Relationship between HER2 status and prognosis in women with brain metastases from breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 82(5), e739-e747 (2012).
12. Sperduto PW, Kased N, Roberge D et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 82 (5), 2111-2117 (2012).
13. Broadbent AM, Hruby G, Tin MM, Jackson M, Firth I. Survival following whole brain radiation treatment for cerebral metastases: an audit of 474 patients. Radiother. Oncol. 71(3), 259-265 (2004).
14. Marsh JC, Gielda BT, Herskovic AM, Abrams RA. Cognitive sparing during the administration of whole brain radiotherapy and prophylactic cranial irradiation: current concepts and approaches. J. Oncol. 2010, 198208 (2010).
15. Roman DD, Sperduto PW. Neuropsychological effects of cranial radiation: current knowledge and future directions. Int. J. Radiat. Oncol. Biol. Phys. 31(4), 983-998 (1995).
16. Welzel G, Fleckenstein K, Schaefer J et al. Memory function before and after whole brain radiotherapy in patients with and without brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 72(5), 1311-1318 (2008).
17. Wronski M, Arbit E, Mccormick B. Surgical treatment of 70 patients with brain metastases from breast carcinoma. Cancer 80(9), 1746-1754 (1997).
18. Pieper DR, Hess KR, Sawaya RE. Role of surgery in the treatment of brain metastases in patients with breast cancer. Ann. Surg. Oncol. 4(6), 481-490 (1997).
19. Goyal S, Prasad D, Harrell F Jr, Matsumoto J, Rich T, Steiner L. g knife surgery for the treatment of intracranial metastases from breast cancer. J. Neurosurg. 103(2), 218-223 (2005).
20. Akyurek S, Chang EL, Mahajan A et al. Stereotactic radiosurgical treatment of cerebral metastases arising from breast cancer. Am. J. Clin. Oncol. 30(3), 310-314 (2007).
21. Williams BJ, Suki D, Fox BD et al. Stereotactic radiosurgery for metastatic brain tumors: a comprehensive review of complications. J. Neurosurg. 111(3), 439-448 (2009).
22. Minniti G, Clarke E, Lanzetta G et al. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat. Oncol. 6, 48 (2011).
23. Patchell RA, Tibbs PA, Walsh JW et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322(8), 494-500 (1990).
24. Vecht CJ, Haaxma-Reiche H, Noordijk EM et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann. Neurol. 33(6), 583-590 (1993).
25. Andrews DW, Scott CB, Sperduto PW et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363(9422), 1665-1672 (2004).
26. Patchell RA, Tibbs PA, Regine WF et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280(17), 1485-1489 (1998).
27. Aoyama H, Shirato H, Tago M et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295(21), 2483-2491 (2006).
28. Kocher M, Soffetti R, Abacioglu U et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study J. Clin. Oncol. 29(2), 134-141 (2011).
29. Aoyama H, Tago M, Kato N et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int. J. Radiat. Oncol. Biol. Phys. 68(5), 1388-1395 (2007).
30. Aoyama H. Radiation therapy for brain metastases in breast cancer patients. Breast Cancer 18(4), 244-251 (2011).
31. Soffetti R, Kocher M, Abacioglu UM et al. A European Organisation for Research and Treatment of Cancer Phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J. Clin. Oncol. 31(1), 65-72 (2013).
32. Kolaric K, Roth A, Jelicic I, Matkovic A. Phase II clinical trial of cis dichlorodiammine platinum (Cis DDP) in metastatic brain tumors. J. Cancer Res. Clin. Oncol. 104(3), 287-293 (1982).
33. Vinolas N, Graus F, Mellado B, Caralt L, Estape J. Phase II trial of cisplatinum and etoposide in brain metastases of solid tumors. J. Neurooncol. 35(2), 145-148 (1997).
34. Franciosi V, Cocconi G, Michiara M et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 85(7), 1599-1605 (1999).
35. Siena S, Crino L, Danova M et al. Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter Phase II study. Ann. Oncol. 21(3), 655-661 (2010).
36. Christodoulou C, Bafaloukos D, Linardou H et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J. Neurooncol. 71(1), 61-65 (2005).
37. Rivera E, Meyers C, Groves M et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 107(6), 1348-1354 (2006).
38. Murphy C, Nulsen B, Rump M et al. Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiotherapy (WBXRT). Presented at: ASCO Breast Cancer Symposium. San Francisco, CA, USA, 2 June 2009.
39. Freedman RA, Bullitt E, Sun L et al. A Phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin. Breast Cancer 11(6), 376-383 (2011).
40. Boogerd W, Dalesio O, Bais EM, van der Sande JJ. Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 69(4), 972-980 (1992).
41. Oberhoff C, Kieback DG, Wurstlein R et al. Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study. Onkologie 24(3), 256-260 (2001).
42. Ekenel M, Hormigo AM, Peak S, Deangelis LM, Abrey LE. Capecitabine therapy of central nervous system metastases from breast cancer. J. Neurooncol. 85(2), 223-227 (2007).
43. Chargari C, Kirova YM, Dieras V et al. Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients. J. Neurooncol. 93(3), 379-384 (2009).
44. Bartsch R, Rottenfusser A, Wenzel C et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J. Neurooncol. 85(3), 311-317 (2007).
45. Church DN, Modgil R, Guglani S et al. Extended survival in women with brain metastases from HER2 overexpressing breast cancer. Am. J. Clin. Oncol. 31(3), 250-254 (2008).
46. Dawood S, Broglio K, Esteva FJ et al. Defning prognosis for women with breast cancer and CNS metastases by HER2 status. Ann. Oncol. 19(7), 1242-1248 (2008).
47. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fuid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 18(1), 23-28 (2007).
48. Dijkers EC, Oude Munnink TH, Kosterink JG et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 87(5), 586-592 (2010).
49. Kinoshita M, Mcdannold N, Jolesz FA, Hynynen K. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc. Natl Acad. Sci. USA 103(31), 11719-11723 (2006).
50. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006).
51. Taskar KS, Rudraraju V, Mittapalli RK et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm. Res. 29(3), 770-781 (2012).
52. Polli JW, Humphreys JE, Harmon KA et al. The role of effux and uptake transporters in [N-{3-chloro-4-[(3-fuorobenzyl)oxy] phenyl}-6-[5-({[2- (methylsulfonyl)ethyl] amino }methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab. Dispos. 36(4), 695-701 (2008).
53. Polli JW, Olson KL, Chism JP et al. An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fuorobenzyl) oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl] amino }methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug. Metab. Dispos. 37(2), 439-442 (2009).
54. Sanna G, Franceschelli L, Rotmensz N et al. Brain metastases in patients with advanced breast cancer. Anticancer Res. 27(4C), 2865-2869 (2007).
55. Onishi H, Morisaki T, Nakafusa Y, Nakashima Y, Yokohata K, Katano M. Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer. Int. J. Clin. Oncol. 16(6), 718-721 (2011).
56. Abboud M, Saghir NS, Salame J, Geara FB. Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent lapatinib and capecitabine. Breast J. 16(6), 644-646 (2010).
57. Gluck S, Castrellon A. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases. Am. J. Ther. 16(6), 585-590 (2009).
58. Lin NU, Dieras V, Paul D et al. Multicenter Phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res. 15(4), 1452-1459 (2009).
59. Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 26(12), 1993-1999 (2008).
60. Sutherland S, Ashley S, Miles D et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including effcacy in brain metastases-the UK experience. Br. J. Cancer 102(6), 995-1002 (2010).
61. Bartsch R, Berghoff A, Pluschnig U et al. Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases. Br. J. Cancer 106(1), 25-31 (2012).
62. Lin NU, Eierman W, Greil R et al. Randomized Phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J. Neurooncol. 105(3), 613-620 (2011).
63. Bachelot T, Romieu G, Campone M et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group Phase 2 study. Lancet Oncol. 14(1), 64-71 (2013).
64. +) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR). Presented at: 2011 ASCO Annual Meeting. Chicago, IL, USA, 5 June 2011.
65. Wen PY, Macdonald DR, Reardon DA et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 28(11), 1963-1972 (2010).
66. Burzykowski T, Buyse M, Piccart-Gebhart MJ et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J. Clin. Oncol. 26(12), 1987-1992 (2008).
67. Gaillard PJ, Gladines W, Appeldoorn CCM. Development of glutathione pegylated liposomal doxorubicin (2B3-101) for the treatment of brain cancer. Cancer Res. 72(8), Abstract 5687 (2012).
68. Kurzrock R, Gabrail N, Chandhasin C et al. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Mol. Cancer Ther. 11(2), 308-316 (2012).
69. Fitzgerald DP, Emerson DL, Qian Y et al. TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells. Mol. Cancer Ther. 11(9), 1959-1967 (2012).
70. Burstein HJ, Sun Y, Dirix LY et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J. Clin. Oncol. 28(8), 1301-1307 (2010).
71. Swaby R, Blackwell K, Jiang Z et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a Phase I/II study. J. Clin. Oncol. (27), Abstract 1004 (2009).
72. Lin NU, Winer EP, Wheatley D et al. A Phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res. Treat. 133(3), 1057-1065 (2012).
73. Yap TA, Vidal L, Adam J et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J. Clin. Oncol. 28(25), 3965-3972 (2010).
74. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366(6), 520-529 (2012).
75. Metro G, Foglietta J, Russillo M et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann. Oncol. 22(3), 625-630 (2011).
76. Macdonald DR, Cascino TL, Schold SC, Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277-1280 (1990).
77. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur. J. Cancer 45, 228-247 (2009).